Xiangcai Securities·2025-10-27 02:50Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Insights - The company reported a revenue growth of 18.61% year-on-year for the first three quarters of 2025, with a non-GAAP net profit growth of 42.51% [3][6] - The TIDES business segment showed exceptional performance, with a revenue increase of 121.1% [8][12] - The company expects its continuous operating business revenue growth to return to double digits, with an adjusted growth forecast of 17-18% for 2025 [11][12] Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 328.57 billion yuan, a year-on-year increase of 18.61%, and a net profit attributable to shareholders of 120.76 billion yuan, up 84.84% [6][7] - The gross margin improved to 46.62%, an increase of 5.97 percentage points year-on-year, while the net margin rose to 37.15%, up 13.32 percentage points [7] Business Segments - The company's revenue from its three main business segments for the first three quarters of 2025 was as follows: - Chemical business: 259.8 billion yuan (+29.28%) - Testing business: 41.69 billion yuan (-0.04%) - Biological business: 19.5 billion yuan (+6.64%) [8] - The chemical business's small molecule D&M revenue was 142.4 billion yuan, a growth of 14.1% [8] Future Outlook - The company has raised its revenue forecast for 2025-2027 to 444.93 billion yuan, 512.59 billion yuan, and 584.79 billion yuan respectively [12] - The adjusted net profit forecasts for the same period are 151.44 billion yuan, 143.44 billion yuan, and 164.82 billion yuan respectively [12]